Patents by Inventor Matthew Cooper

Matthew Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220158405
    Abstract: Apparatus and methods for mitigating transverse mode instabilities (TMI) in high power fiber amplifiers that does not depend on active feedback loops. The apparatus and method involve the modulation of the amplitude and/or phase of selected spatial mode components of an input signal beam to increase the TMI threshold of the amplifier. Once the desired modal adjustments are made, the beam is input to a mode multiplexer whereupon an optimized output beam can be input to the active fiber of the amplifier system. By increasing the TMI threshold of the amplifier, the amplifier can be operated at higher power before TMI sets in. A control stage of the fiber amplifier system includes (a) a (seed) beam splitting section; (b) an amplitude and phase control component; and (c) a mode multiplexer that maps multiple individual signal beams to different fiber modes.
    Type: Application
    Filed: November 19, 2021
    Publication date: May 19, 2022
    Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Steffen Wittek, Juan Carlos Alvarado Zacarias, Daniel Cruz Delgado, Jose Enrique Antonio Lopez, Rodrigo Amezcua Correa, Matthew Cooper
  • Patent number: 11333672
    Abstract: Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: May 17, 2022
    Assignee: PROGENITY, INC.
    Inventors: Matthew Cooper, Sharat Singh, Karen A. F. Copeland, Lyndal Hesterberg, Amin R. Mazloom, Mohammad Abbasi, Richard Giulio Del Mastro
  • Publication number: 20220112159
    Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
    Type: Application
    Filed: August 18, 2021
    Publication date: April 14, 2022
    Inventors: Luke O'NEILL, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
  • Publication number: 20220106289
    Abstract: The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.
    Type: Application
    Filed: November 22, 2019
    Publication date: April 7, 2022
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jonathan SHANNON, Stephen THOM, Ian STRUTT, Diana CASTAGNA, Jokin CARRILLO ARREGUI, Jimmy VAN WILTENBURG
  • Patent number: 11279733
    Abstract: There is provided a range of novel compounds. These novel compounds may demonstrate abroad spectrum antibacterial and antifungal activity. These compounds may be active against the emerging polymyxin resistant bacteria. These compounds may also be useful when used in conjunction with other pharmaceutically active agents.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 22, 2022
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Matthew Cooper, Mark Blaskovich, Alejandra Gallardo-Godoy, Karl Hansford, Alysha Elliott, Craig Muldoon, Bernd Becker
  • Publication number: 20220066426
    Abstract: Adaptable manufacturing systems, methods, and apparatuses are disclosed. An apparatus for manufacturing a product in accordance with the present disclosure may include a design apparatus, an assembly apparatus, and a control apparatus, coupled to the design apparatus and the assembly apparatus. The control apparatus receives input information from the design apparatus and the assembly apparatus. The control apparatus provides output information for altering at least one parameter used by at least one of the design apparatus and the assembly apparatus in the manufacture of the product.
    Type: Application
    Filed: June 9, 2021
    Publication date: March 3, 2022
    Inventors: Kevin Robert CZINGER, Michael Thomas KENWORTHY, Lukas Philip CZINGER, Jinbo CHEN, Antonio Bernerd MARTINEZ, Matthew Cooper KELLER, Alex James HAMADE
  • Publication number: 20220060838
    Abstract: Methods for dialogue enhancing audio content, comprising providing a first audio signal presentation of the audio components, providing a second audio signal presentation, receiving a set of dialogue estimation parameters configured to enable estimation of dialogue components from the first audio signal presentation, applying said set of dialogue estimation parameters to said first audio signal presentation, to form a dialogue presentation of the dialogue components; and combining the dialogue presentation with said second audio signal presentation to form a dialogue enhanced audio signal presentation for reproduction on the second audio reproduction system, wherein at least one of said first and second audio signal presentation is a binaural audio signal presentation.
    Type: Application
    Filed: September 2, 2021
    Publication date: February 24, 2022
    Applicants: Dolby Laboratories Licensing Corporation, Dolby International AB
    Inventors: Leif Jonas SAMUELSSON, Dirk Jeroen BREEBAART, David Matthew COOPER, Jeroen KOPPENS
  • Publication number: 20210347737
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas of formula (I) comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, and wherein the group attached to the terminal nitrogen atom of the urea group is either a 1,2, 3,5,6, 7-hexahydro-s-indacen-4-yl group substituted at the 8-position, or a heteroaryl group substituted at the alpha and alpha? positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: March 1, 2019
    Publication date: November 11, 2021
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jonathan SHANNON
  • Publication number: 20210332020
    Abstract: The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.
    Type: Application
    Filed: March 1, 2019
    Publication date: October 28, 2021
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD
  • Publication number: 20210299223
    Abstract: Disclosed herein are therapeutic uses for treating cancer in a subject in need thereof, comprising administering to the subject a population of chimeric antigen receptor (CAR)-bearing immune effector cells and an IL-7 protein (e.g., modified IL-7 protein).
    Type: Application
    Filed: July 30, 2019
    Publication date: September 30, 2021
    Applicants: WASHINGTON UNIVERSITY, NEOIMMUNETECH, INC.
    Inventors: John F. DIPERSIO, Matthew COOPER, Karl STASER, Jaehan PARK, Byung Ha LEE, Dong Hoon CHOI
  • Patent number: 11130731
    Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: September 28, 2021
    Assignees: The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The University Of Queensland
    Inventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
  • Publication number: 20210295852
    Abstract: A method for encoding an input audio stream including the steps of obtaining a first playback stream presentation of the input audio stream intended for reproduction on a first audio reproduction system, obtaining a second playback stream presentation of the input audio stream intended for reproduction on a second audio reproduction system, determining a set of transform parameters suitable for transforming an intermediate playback stream presentation to an approximation of the second playback stream presentation, wherein the transform parameters are determined by minimization of a measure of a difference between the approximation of the second playback stream presentation and the second playback stream presentation, and encoding the first playback stream presentation and the set of transform parameters for transmission to a decoder.
    Type: Application
    Filed: April 8, 2021
    Publication date: September 23, 2021
    Applicants: DOLBY LABORATORIES LICENSING CORPORATION, DOLBY INTERNATIONAL AB
    Inventors: Dirk Jeroen Breebaart, David Matthew Cooper, Leif Jonas Samuelsson, Jeroen Koppens, Rhonda J. Wilson, Heiko Purnhagen, Alexander Stahlmann
  • Publication number: 20210293824
    Abstract: Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.
    Type: Application
    Filed: April 19, 2021
    Publication date: September 23, 2021
    Inventors: Matthew COOPER, Sharat SINGH, Karen A. F. COPELAND, Lyndal HESTERBERG, Amin R. MAZLOOM, Mohammad ABBASI, Richard Giulio DEL MASTRO
  • Patent number: 11115768
    Abstract: Methods for dialogue enhancing audio content, comprising providing a first audio signal presentation of the audio components, providing a second audio signal presentation, receiving a set of dialogue estimation parameters configured to enable estimation of dialogue components from the first audio signal presentation, applying said set of dialogue estimation parameters to said first audio signal presentation, to form a dialogue presentation of the dialogue components; and combining the dialogue presentation with said second audio signal presentation to form a dialogue enhanced audio signal presentation for reproduction on the second audio reproduction system, wherein at least one of said first and second audio signal presentation is a binaural audio signal presentation.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: September 7, 2021
    Assignees: Dolby Laboratories Licensing Corporation, Dolby International AB
    Inventors: Leif Jonas Samuelsson, Dirk Jeroen Breebaart, David Matthew Cooper, Jeroen Koppens
  • Patent number: 11054348
    Abstract: A die arrangement for pressing, sintering or stamping comprising: a die body with a cavity extending from an opening at a first end of said die body to an opening at a second end of said die body, and one or more moving parts arranged around the opening at said first end of said die body, wherein each moving part is displaceable between a first position and a second position. The die body may be configurable to receive a die plunger at said second end of said die body, said plunger being displaceable within the cavity.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: July 6, 2021
    Assignee: Specac Limited
    Inventors: Ian Gaskin, Matthew Cooper, Anthony Atkins, Richard Lock
  • Publication number: 20210168553
    Abstract: A system and method of modifying a binaural signal using headtracking information. The system calculates a delay, a first filter response, and a second filter response, and applies these to the left and right components of the binaural signal according to the headtracking information. The system may also apply headtracking to parametric binaural signals. In this manner, headtracking may be applied to pre-rendered binaural audio.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 3, 2021
    Inventors: C. Phillip Brown, Joshua Brandon Lando, Mark F. Davis, Alan J. Seefeldt, David Matthew Cooper, Dirk Jeroen Breebaart, Rhonda Wilson
  • Publication number: 20210147349
    Abstract: The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted either (i) at the ortho-position with a halo group, or (ii) at the meta- and para-positions, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted across the 2,3-positions with a fused ring and further substituted at the 4-position. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: March 1, 2019
    Publication date: May 20, 2021
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD
  • Publication number: 20210130329
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, wherein at least one of the di-substituents contains a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 15, 2018
    Publication date: May 6, 2021
    Applicant: Inflazome Limited
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT
  • Publication number: 20210130359
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group R1? wherein R1 contains from 1 to 7 atoms other than hydrogen or halogen. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 15, 2018
    Publication date: May 6, 2021
    Applicant: Inflazome Limited
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT, Jokin CARRILLO ARREGUI
  • Publication number: 20210122716
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a monocyclic imidazolyl group. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 15, 2018
    Publication date: April 29, 2021
    Applicant: Inflazome Limited
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON